The FDA’s equivalent of a red card – a CRL (complete response letter) – got handed out on June 19 to Nabriva Therapeutics …
In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to …
Analyst believes impressive Phase 3 data read-out bolsters expectations for lefamulin’s peak sales potential.
